Articles

Poll

Podcasts

Slideshows

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

GLP-1 RAs and the Move to Combination Therapy in 2025, with Ankeet Bhatt, MD, MBA

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

GLP-1 RAs and the Future of Cardiology, with Christian Ruff, MD, MPH

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Latest in Lipids and Trials to Watch in 2025, with Viet Le, DMSc, PA-C

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.



Q1 2025 Recap: Cardiology News and Updates

A propensity score-matched study from ASH 2024 suggests GLP-1 RA use reduced VTE risk in type 2 diabetes.

GLP-1 Receptor Agonists Could Reduce Stroke Risk in Type 2 Diabetes

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

Cardiology Month in Review: August 2024

Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.

Disease Status Influences VTE Risk in Women with Sickle Cell Disease

A recent analysis found risk factors linked to an embolism after VTE included Black race, interstitial fibrosis, advanced-stage disease, and increased operative duration.

Study Identifies Critical Risk Factors for VTE After Pulmonary Resection 

Presented at ASH 2023, findings of a new study showed patients with sickle cell disease and venous thromboembolism have longitudinal worsening of left ventricular diastolic and right-sided cardiac function.

Sickle Cell Disease with Venous Thromboembolism Linked to Higher Mortality

Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.

Abelacimab Demonstrates "Overwhelming" Efficacy vs Rivaroxaban in Phase 2b Trial

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.